

*Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.
In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.*

[Translation]

Results of the Exercise of Voting Rights of the 19th Term Annual Shareholders Meeting

The results of the exercise of voting rights of the 19th Term Annual Shareholders Meeting of Astellas Pharma Inc. (the “Company”) held on June 20, 2024 are as follows.

1. Details of matters to be resolved

First Proposal: Election of Seven (7) Directors (Excluding Directors Who Are Audit & Supervisory Committee Members)

To elect Dr. Kenji Yasukawa, Mr. Naoki Okamura, Mr. Katsuyoshi Sugita, Mr. Takashi Tanaka, Ms. Eriko Sakurai, Mr. Masahiro Miyazaki and Dr. Yoichi Ohno

Second Proposal: Election of Three (3) Directors Who are Audit & Supervisory Committee Members

To elect Dr. Rika Hirota, Ms. Mika Nakayama and Ms. Tomoko Aramaki

2. Numbers of voting rights for approval of, against and abstaining from each of the matters to be resolved, requirements for each of the matters to be resolved to be approved and the results for each resolution

Matters to be resolved	Approval	Against	Abstention	Proportion of approval	Result	Approval requirements
First Proposal						
Kenji Yasukawa	12,907,415	1,092,431	6,136	92.1%	Approval	Note)
Naoki Okamura	12,924,429	1,075,404	6,150	92.2%	Approval	
Katsuyoshi Sugita	13,488,669	511,517	5,797	96.3%	Approval	
Takashi Tanaka	13,224,766	774,932	6,280	94.4%	Approval	
Eriko Sakurai	13,498,178	501,544	6,260	96.3%	Approval	
Masahiro Miyazaki	13,813,583	186,140	6,259	98.6%	Approval	
Yoichi Ohno	13,815,000	184,722	6,260	98.6%	Approval	
Second Proposal						
Rika Hirota	12,458,466	1,543,391	6,054	88.9%	Approval	Note)
Mika Nakayama	13,824,919	176,885	6,126	98.6%	Approval	
Tomoko Aramaki	13,669,736	332,073	6,125	97.5%	Approval	

Note) Approval requires i) the attendance of shareholders possessing at least one-third (1/3) of the voting rights of shareholders who are eligible to exercise voting rights and ii) an affirmative vote of a majority of the voting rights of shareholders in attendance.